Celera Genomics Purchases Rights to Preclinical Asthma Compounds from Bayer
Rockville, MD - October 08, 2002
Celera Genomics Group (NYSE: CRA), an Applera Corporation business, today announced that it has purchased from Bayer AG (NYSE: BAY) of Leverkusen, Germany, all rights under the existing collaboration between the companies. Celera has acquired rights to all compounds, study data and relevant intellectual property pertaining to their use in all fields, including the primary area of application, oral agents for the treatment of asthma. In connection with the purchase, the parties agreed to terminate the collaborative research and license agreement established in November 1994 by Arris Pharmaceutical Corporation, a predecessor of Axys Pharmaceuticals, a company purchased by Celera in November 2001, and now operated as Celera South San Francisco.Financial terms of the transaction were not disclosed.
“Our objective is to build a therapeutic development portfolio consisting of clinical and preclinical compounds,” said Kathy Ordoñez, President, Celera Genomics. “The acquisition of these compounds and rights supports that goal.”
“We plan to obtain pilot scale quantities of these compounds, and to complete additional IND-enabling toxicology and safety evaluations in the coming months,” said Robert Booth, Ph.D., Senior Vice President of Research & Development, Celera Genomics.
About Celera Genomics and Applera Corporation
Applera Corporation comprises two operating groups. The Celera Genomics Group, located in Rockville, MD, and South San Francisco, CA, is engaged principally in integrating advanced technologies to discover and develop new therapeutics. Celera intends to leverage its proteomics, bioinformatics, and genomics capabilities to identify and validate drug targets and diagnostic marker candidates, and to discover and develop novel therapeutic candidates. Its Celera Discovery SystemTM online platform, marketed exclusively through the Knowledge Business of Applied Biosystems, is an integrated source of information based on the human genome and other biological and medical sources. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2002. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of novel diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at www.applera.com, or by telephoning 800.762.6923. Information about Celera Genomics is available at www.celera.com.
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as “believe,” “expect,” “intend,” “anticipate,” “should,” “planned,” and “potential,” among others. These forward-looking statements are based on Applera Corporation’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties include but are not limited to (1) Celera Genomics’ unproven ability to discover, develop, or commercialize proprietary therapeutic or diagnostic products, the risk that clinical trials of products they do discover and develop will not proceed as anticipated or may not be successful, the uncertainty that such products will not be accepted and adopted by the market, and the risk that that such products will not receive required regulatory approvals; (2) Celera Genomics’ reliance on access to biological materials and related clinical and other information, which may be in limited supply or access to which may be limited; (3) the risk that certain raw materials and equipment required by Celera Genomics, including preclinical compounds, may not be available or may not be available at acceptable prices; and (4) other factors that might be described from time to time in Applera Corporation’s filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.
Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.